Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Day One Biopharmaceuticals logo — Cancer drug development comes of age.

Day One Biopharmaceuticals

Cancer drug development comes of age.

Founded 2018 United States Brisbane, United States 190 employees Post Ipo Equity Total: $687.50M Biopharma, Biotechnology +2

General Information

Company Name Day One Biopharmaceuticals
Founded Year 2018
Location United States Brisbane, United States +1
Founders / Decision Makers
Team member
Employees 190
Industries Biopharma, Biotechnology, Health Care +1
Funding Stage Post Ipo Equity
Social

Get notified when Day One Biopharmaceuticals moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Day One Biopharmaceuticals

Day One Biopharmaceuticals is a pioneering biotechnology company established in 2018 in the United States. The company's mission is encapsulated in its slogan, "Cancer drug development comes of age." Day One Biopharmaceuticals is poised at the forefront of cancer research, aiming to facilitate the identification and development of innovative therapies that cater to the critical needs of patients across all age groups. Leveraging a distinctive approach and a robust network of pediatric oncology investigators, the company is uniquely positioned to advance pioneering discoveries for patients of any age. Day One Biopharmaceuticals has recently secured a substantial $150.00M Post-IPO Equity investment on 06 June 2023, signifying a strong vote of confidence in the company's vision and potential. This significant investment underscores the industry's recognition of Day One Biopharmaceuticals' capacity to drive impactful change in the field of cancer treatment. With its dedication to harnessing the full potential of its therapies to enhance countless lives expeditiously, Day One Biopharmaceuticals stands as a pivotal player in the biopharma, biotechnology, healthcare, and pharmaceutical sectors. This company's steadfast commitment and recent substantial investment position it as a compelling prospect for venture capital consideration.

Taxonomy: Cancer drug development, Pediatric oncology, Therapeutic advancements, Biology of cancer, Research and development, Precision medicine, Patient-focused therapies, Medical innovation, Clinical trials, Drug discovery, Biopharmaceutical company, Oncology treatments

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• 6
Investor Investor Investor Investor
•••• •••• 		30 Jul 2024
Post-IPO Equity •••••• - 06 Jun 2023
Post-IPO Equity •••••• - 14 Jun 2022
Series B •••••• 4
Investor Investor Investor Investor
10 Feb 2021
Series A •••••• - 21 May 2020

Day One Biopharmaceuticals Alternatives & Competitors

Day One Biopharmaceuticals vs
ApoGen Biotechnologies, Inc.
ApoGen Biotechnologies, Inc. United States

As the arsenal of available cancer therapies has grown and evolved from cytotoxic chemotherapy to ta...

Series A
1 employees
Biotechnology, Health Care
Compare Day One Biopharmaceuticals vs ApoGen Biotechnologies, Inc.
Day One Biopharmaceuticals vs
Fore Biotherapeutics
Fore Biotherapeutics United States

A precision oncology company rooted in science and innovation, developing cancer therapies guided by...

Series D
46 employees
Biotechnology, Health Care
Compare Day One Biopharmaceuticals vs Fore Biotherapeutics
Day One Biopharmaceuticals vs
Probmet Therapeutics
Probmet Therapeutics Denmark

An oncology therapeutics company developing new targeted treatments for breast cancer brain metastat...

Convertible Note
2 employees
Health Care, Health and Wellness
Compare Day One Biopharmaceuticals vs Probmet Therapeutics

FAQ About Day One Biopharmaceuticals

Cancer drug development comes of age.
Day One Biopharmaceuticals was founded in 2018.
Day One Biopharmaceuticals is headquartered in Brisbane, United States.
Day One Biopharmaceuticals operates in the following industries: Biopharma, Biotechnology, Health Care, Pharmaceutical.
Day One Biopharmaceuticals has approximately 190 employees.
Day One Biopharmaceuticals has completed 5 funding rounds, raising a total of $687.50M. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to Day One Biopharmaceuticals include ApoGen Biotechnologies, Inc., Fore Biotherapeutics, Probmet Therapeutics, Cornerstone Pharmaceuticals, Cumulus Oncology. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Day One Biopharmaceuticals and ApoGen Biotechnologies, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Day One Biopharmaceuticals and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes